Spero Therapeutics Appoints New CEO Esther Rajavelu

Spero Therapeutics ( (SPRO) ) has shared an announcement.

On April 28, 2025, Spero Therapeutics announced the appointment of Esther Rajavelu as President and Chief Executive Officer, effective May 2, 2025. Rajavelu, who has been serving as Interim President and CEO since January 2025, will also continue her roles as Chief Financial Officer and Treasurer. This leadership transition follows the mutual separation of former CEO Sath Shukla, who will step down on the same effective date. The company is focused on advancing its PIVOT-PO Phase 3 trial for tebipenem HBr, with Rajavelu’s leadership expected to strengthen Spero’s strategic initiatives and partnerships, particularly with GSK.

Spark’s Take on SPRO Stock

According to Spark, TipRanks’ AI Analyst, SPRO is a Neutral.

Spero Therapeutics is currently facing financial and operational challenges, highlighted by declining revenues and increased losses. The financial performance and technical analysis suggest a cautious outlook, while the earnings call provides some optimism through strategic partnerships and potential milestone payments. However, the negative valuation metrics and recent clinical trial setbacks weigh heavily on the stock score, resulting in an overall score of 53.

To see Spark’s full report on SPRO stock, click here.

More about Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need.

YTD Price Performance: -32.87%

Average Trading Volume: 171,384

Technical Sentiment Signal: Buy

Current Market Cap: $40.54M

See more insights into SPRO stock on TipRanks’ Stock Analysis page.